GM Joins the STAR Hunt

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 4
Volume 10
Issue 4

BETHESDA, Md-General Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female

BETHESDA, Md—General Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen and Raloxifene (STAR), to 140,000 of its active and retired salaried female employees. STAR researchers have enrolled more than 8,500 of a planned accrual of 22,000 postmenopausal women age 35 and older. The trial compares Evista (raloxifene) and Nolvadex (tamoxifen) for reducing breast cancer risk.

Articles in this issue
IOM Urges Action to Fix ‘Broken’ US Health Care System
Thompson Pledges Fundamental HCFA Reform
NCCN Updates Its Practice Guideline for Breast Cancer
Smoking Prevalence, Mortality Ranges Widely From State to State
NCI Debuts New Program for Cancer Advocates
Fiberoptic Ductoscopy for Nipple Discharge DisWomen With Nipple Discharge
Augmerosen, Antisense Drug, in Phase III Testing in Melanoma
Automated System Improves Accuracy of HER-2 Scoring
Small Advantage for Adjuvant Paclitaxel in Early Breast Cancer
New HIV Guidelines Lower the Count for Starting Therapy Antiretroviral Therapy
Prostate Cancer Research at UCSF Focuses on Dendritic Cells
Pretransplant Mylotarg Boosts Survival in Relapsed AML
Thalidomide Demonstrates Multiple Roles in Myeloma
DepoCyt, Liposomal Cytarabine, Reintroduced Into US Market
Film Mammography Still the Gold Standard: IOM Report
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
August 30th 2025
Article

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
August 28th 2025
Article

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
August 13th 2025
Article

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
August 12th 2025
Article

Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.